Medoflucon

Fluconazole, the active ingredient in Medoflucon, is an azole antifungal presented as an oral tablet for oral use. It treats systemic and mucosal fungal infections in adults and children as prescribed.

GNH USA supplies Medoflucon as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Medoflucon, an azole antifungal, is employed to manage infections caused by susceptible fungi.

- Candidiasis (oropharyngeal, esophageal, vaginal): clears yeast overgrowth and relieves associated symptoms. - Cryptococcal meningitis: penetrates the central nervous system to eradicate Cryptococcus neoformans. - Dermatophyte infections: treats skin and nail fungal infections. - Systemic candidiasis: eliminates invasive Candida species from the bloodstream and organs.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Nausea - Headache - Abdominal pain - Diarrhea - Rash - Altered taste perception

Serious or Rare Side Effects: - Severe liver injury (hepatitis, hepatic failure) - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Anaphylaxis or severe allergic reactions - Hematologic abnormalities (e.g., agranulocytosis, pancytopenia) - QT interval prolongation - Severe skin reactions such as drug‑induced hypersensitivity syndrome

Before initiating Medoflucon, clinicians should consider several safety measures.

- Assess liver function: monitor hepatic enzymes prior to and during treatment. - Evaluate renal function: adjust dose in patients with severe renal impairment. - Review concomitant medications: identify potential drug‑drug interactions. - Use with caution in pregnancy: prescribe only when benefits outweigh potential risks. - Store at room temperature: keep in the original pack, protect from moisture and light.

Fluconazole can affect the plasma levels of several co‑administered drugs.

Major Interactions (Avoid): - Warfarin: increased anticoagulant effect and INR. - Rifampin: reduced fluconazole exposure, compromising efficacy. - Certain antiretrovirals (e.g., efavirenz): decreased fluconazole levels. - Oral contraceptives: reduced hormonal efficacy, risk of breakthrough bleeding. - Phenytoin: lowered phenytoin concentrations.

Moderate Interactions (Monitor Closely): - Statins (simvastatin, lovastatin): increased risk of myopathy. - Benzodiazepines (midazolam, triazolam): enhanced sedation. - Macrolide antibiotics (erythromycin, clarithromycin): elevated plasma concentrations.